SU3327 NEW
| Price | $32 | $59 | $97 |
| Package | 2mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: SU3327 | CAS No.: 40045-50-9 |
| Purity: 98.39% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | SU3327 |
| Description | SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM). |
| In vitro | TNF-α stimulated phosphorylation of c-Jun in HeLa cells inhibited by SU3327 with EC50 of 6.23 μM[1]. SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1[3]. |
| In vivo | In male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice, SU3327 (25 mg/kg; intraperitoneal injection; ) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1]. SU3327 has favorable microsomal and plasma stability (T1/2 = 27 min)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2.5 mg/mL (9.57 mM), Sonication is recommended. DMSO : 83.3 mg/mL (318.79 mM), Sonication is recommended. 10% DMSO+90% Saline : < 8.33 mg/mL (31.88 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8.33 mg/mL (31.88 mM), Solution. |
| Keywords | TNF-α | Thiadiazole | substrate-competitive | SU-3327 | SU3327 | SU 3327 | protein-protein | PPI | phosphorylation | p38α | JNK-JIP interactions | JNK | JIP | insulin | Inhibitor | inhibit |
| Inhibitors Related | Astragaloside IV | Teneligliptin hydrobromide | Berberine hydrogen sulphate | SP600125 | Chloranil | (-)-Bornyl acetate | Benzbromarone | Anisomycin | Chloramphenicol | Metacetamol | Berberine sulfate | Benzyl salicylate |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Diabetic Compound Library | Kinase Inhibitor Library | Pyroptosis Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $32.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
|
VIP2Y
|
Hubei Lidu New Material Technology Co., Ltd
|
2026-07-01 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY